New Delhi : Cipher Pharma Inc, along with partners Ranbaxy – a Sun Pharma firm – and Galephar Pharmaceutical Research, has entered into a patent litigation settlement with Actavis over generic version of Absorica, a drug used to treat acne, reports PTI.

The company, along with its two partners, has entered into a settlement agreement with Actavis Laboratories, Andrx Corp, Actavis Inc and Actavis Pharma, that dismisses the patent litigation suit relating to Actavis’ ANDA for a generic version of Absorica, Cipher said.

As a part of the settlement, Actavis has got non-exclusive licence under which it may begin selling generic Absorica in the US on Dec 27, 2020 or earlier under certain circumstances, Cipher said in the release. The patents relating to Absorica expire in September 2021.

(For all the latest News, Mumbai, Entertainment, Cricket, Business and Featured News updates, visit Free Press Journal. Also, follow us on Twitter and Instagram and do like our Facebook page for continuous updates on the go)

Free Press Journal